NCT07480421 (Neo-Matrix) is a NA clinical trial of Acellular matrix in Breast Reconstruction, sponsored by Silimed Industria de Implantes Ltda.

Who is sponsoring NCT07480421?

NCT07480421 is sponsored by Silimed Industria de Implantes Ltda.

What drugs are being tested in NCT07480421?

Interventions in NCT07480421: Acellular matrix.

What condition does NCT07480421 study?

NCT07480421 studies Breast Reconstruction.

Is NCT07480421 still recruiting?

NCT07480421 is currently not yet recruiting. Last updated 20 March 2026.

Last reviewed 2026-03-20 · How we verify

NCT07480421: Neo-Matrix

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Evaluation of Neorepair™ Acellular Matrix in Immediate Implant-Based Breast Reconstruction

Not yet recruiting NA Last updated 20 March 2026

What this trial tests

NA trial testing Acellular matrix in Breast Reconstruction in 100 participants. Not yet recruiting.

Timeline

1 July 2026

Primary endpoint
30 June 2029

30 June 2029

Quick facts

Lead sponsor	Silimed Industria de Implantes Ltda
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 July 2026
Primary completion	30 June 2029
Estimated completion	30 June 2029
Sites	1 location across Brazil

Drugs / interventions tested

Acellular matrix

Conditions studied

Breast Reconstruction — all drugs for Breast Reconstruction →

Sponsor

Silimed Industria de Implantes Ltda — full company profile →

Who can join

18 and older, female only, with Breast Reconstruction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study investigates the safety and performance of Silimed® brand acellular matriz in women born female with indication for breast reconstruction. The safety of the acellular matriz will be evaluated by estimating known and unexpected adverse event rates assessed by clinical evaluations and patient reports of adverse events after implantation in addition to monitoring integration by Magnetic Resonance Imaging (MRI). The performance of Silimed® brand acellular matriz will be evaluated by clinical effectiveness of the acellular matrix in supporting breast reconstruction, reflected by the structural and functional maintenance of the reconstructed tissue without the occurrence of major complications related to integration failure during the follow-up period. Secondary performance outcomes include: assessment of body image-related quality of life, self-esteem assessment, aesthetic and functional breast assessment, and participant satisfaction level.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Reconstruction

Currently open trials in the same condition.

NCT07230535 — Evaluation of Wellbeing and Patient Reported Outcomes After Open vs Robotic Mastectomy With DIEP Reconstruction · NA · recruiting
NCT07293052 — Comparison of Outcome Between Grisotti Flap Versus Reverse Mirror Grisotti Flap for Central Quadrant Breast Tumors · NA · active not recruiting
NCT07331753 — The Outcomes of Fat Grafting Combined With Latissimus Dorsi Muscle Flap for Delayed Breast Reconstruction After Mastecto · NA · recruiting
NCT07185334 — Single-Stage Prepectoral Placement of Textured Implants Using a Polyester Mesh Endoprostheses With Fluoropolymer Coating · NA · active not recruiting
NCT06993714 — 3D-printed Biodegradable Breast Implants for Breast Restoration · Phase 2 · recruiting

Other Silimed Industria de Implantes Ltda trials

Trials by the same sponsor.

NCT06981481 — Post-marketing Clinical Monitoring of Safety and Performance of Breast Tissue Expander for Breast Reconstruction · recruiting
NCT05997654 — Evaluation of the Safety and Effectiveness of the Investigational Product in Improvement of the Appearance of Wrinkles a · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07480421 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Silimed Industria de Implantes Ltda
Last refreshed: 20 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07480421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing